Up to 60% of Crohn disease patients taking an anti—tumor necrosis factor (TNF) monoclonal antibody medication eventually stop responding to treatment, but the optimal management of these patients has not been clearly defined.
Up to 60% of Crohn disease (CD) patients taking an anti—tumor necrosis factor (TNF) monoclonal antibody medication eventually stop responding to treatment, but the optimal management of these patients has not been clearly defined.
A recent review and meta-analysis by Christian Pagnini, MD, PhD, and colleagues, published in Gastroenterology Research and Practice concludes that there is an increasing number of treatment choices for such anti-TNF failures, including using a second anti-TNF monoclonal antibody, and biologics with alternative mechanism of action, such as the anti-integrins vedolizumab (reference biologic, Entyvio) and natalizumab (reference biologic, Tysabri), and the anti-interleukin (IL)-12/IL-23 antibody ustekinumab (reference biologic, Stelara).1 The study found that no specific agent was shown to be clearly superior to others among the only available indirect comparisons currently in the literature.
The analysis relied on 8 randomized, controlled trials (RCTs) involving 1281 CD patients who were treated with biologics and 733 CD patients who received placebo. All 8 RCTs had 2 arms, with one being placebo administration. Anti-TNF treatment failures were defined as patients who failed to respond (primary failure), those who lost their initial response (secondary failure), and those who were forced to discontinue therapy due to toxicity concerns.
Treatment with a second biologic was found to be superior to placebo for both induction of remission (odds ratio [OR] 2.2; 95% confidence interval [CI], 1.7-3) and response (OR 1.9; 95% CI, 1.5-2.5), with global rates of 24% and 42%, respectively (placebo rate: 11% and 27%; P<.0001 for both). Although no specific agent was found to be clearly superior to others, adalimumab performed relatively better with inducing disease remission, followed by vedolizumab.
Further research is needed to identify optimal management strategies for this challenging subset of patients, the study authors note. Because, for several years, anti-TNF inhibitors have been the only available option for biologic treatment (except for natalizumab, which had limited availability), the number of patients in this hard-to-treat group is rapidly increasing, and guidance about their management is an urgent need. Despite the encouraging findings, the authors note that an improved characterization and classification of CD patients is needed, with the aid of relevant molecular biomarkers or clinical features in order to appropriately identify disease phenotypes with specific responses to selected therapeutic regimens.
“The end goal should be a highly tailored therapy with improved efficacy and outcomes in all patients, minimizing unnecessary drug exposure and adverse events,” the authors conclude.
Reference
Pagnini C, Siakavellas SI, Bamias G. Systematic review with network meta-analysis: efficacy of induction therapy with a second biological agent in anti-TNF-experienced Crohn’s disease patients. Gastroenterol Res Pract. 2018; 2018:6317057. doi.org/10.1155/2018/6317057. eCollection 2018.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.